Related Experiment Video
Updated: May 13, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Nanoparticle accumulation in angiogenic tissues: towards predictable pharmacokinetics
Kristin Yaehne1, Amy Tekrony, Aisling Clancy
1Department of Chemistry, 2500 University Dr NW, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.
Small (Weinheim an Der Bergstrasse, Germany)
|March 7, 2013
Summary
Nanoparticle deposition into tumor blood vessels depends on size and surface charge. Adjusting nanoparticle size can optimize drug delivery for cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Nanoparticles are vital for medical applications like cancer drug delivery, imaging, and diagnostics.
- Current nanoparticle design for tumor delivery lacks quantitative data on angiogenic tissue sequestration.
Purpose of the Study:
- To quantitatively determine nanoparticle deposition rate constants into angiogenic blood vessel tissue.
- To investigate the influence of nanoparticle properties (size, surface charge) on tissue sequestration.
Main Methods:
- Utilized fluorescence correlation spectroscopy (FCS) to measure nanoparticle deposition rates.
- Investigated nanoparticle uptake mechanisms in angiogenic tissue models.
Main Results:
- Nanoparticle deposition is significantly dependent on surface charge.
- Size dependency indicates a passive uptake mechanism governed by nanoparticle geometry.
- Quantitative data on deposition rate constants were established.
Conclusions:
- Nanoparticle pharmacokinetics can be tuned by adjusting nanoparticle size.
- Surface charge and size are critical parameters for optimizing nanoparticle-based cancer drug delivery.
- Findings provide a basis for rational design of targeted nanoparticles.
Related Concept Videos
01:19Nonlinear Pharmacokinetics: Overview
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
01:21Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...